198 related articles for article (PubMed ID: 24472670)
1. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis.
Wong D; Kandagatla P; Korz W; Chinni SR
BMC Urol; 2014 Jan; 14():12. PubMed ID: 24472670
[TBL] [Abstract][Full Text] [Related]
2. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
Huang EH; Singh B; Cristofanilli M; Gelovani J; Wei C; Vincent L; Cook KR; Lucci A
J Surg Res; 2009 Aug; 155(2):231-6. PubMed ID: 19482312
[TBL] [Abstract][Full Text] [Related]
3. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth.
Porvasnik S; Sakamoto N; Kusmartsev S; Eruslanov E; Kim WJ; Cao W; Urbanek C; Wong D; Goodison S; Rosser CJ
Prostate; 2009 Sep; 69(13):1460-9. PubMed ID: 19588526
[TBL] [Abstract][Full Text] [Related]
4. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer.
Drenckhan A; Kurschat N; Dohrmann T; Raabe N; Koenig AM; Reichelt U; Kaifi JT; Izbicki JR; Gros SJ
J Surg Res; 2013 Jun; 182(2):250-6. PubMed ID: 23117118
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
Hassan S; Buchanan M; Jahan K; Aguilar-Mahecha A; Gaboury L; Muller WJ; Alsawafi Y; Mourskaia AA; Siegel PM; Salvucci O; Basik M
Int J Cancer; 2011 Jul; 129(1):225-32. PubMed ID: 20830712
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.
Kim SY; Lee CH; Midura BV; Yeung C; Mendoza A; Hong SH; Ren L; Wong D; Korz W; Merzouk A; Salari H; Zhang H; Hwang ST; Khanna C; Helman LJ
Clin Exp Metastasis; 2008; 25(3):201-11. PubMed ID: 18071913
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
8. In vitro effects and mathematical modelling of CTCE-9908 (a chemokine receptor 4 antagonist) on melanoma cell survival.
Basson C; Phiri AE; Gandhi M; Anguelov R; Serem JC; Bipath P; Hlophe YN
Clin Exp Pharmacol Physiol; 2024 Jun; 51(6):e13865. PubMed ID: 38692577
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.
Singh B; Cook KR; Martin C; Huang EH; Mosalpuria K; Krishnamurthy S; Cristofanilli M; Lucci A
Clin Exp Metastasis; 2010 Apr; 27(4):233-40. PubMed ID: 20229045
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
11. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
[TBL] [Abstract][Full Text] [Related]
12. Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice.
Ni F; Gong Y; Li L; Abdolmaleky HM; Zhou JR
PLoS One; 2012; 7(6):e38802. PubMed ID: 22693649
[TBL] [Abstract][Full Text] [Related]
13. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
Chinni SR; Yamamoto H; Dong Z; Sabbota A; Bonfil RD; Cher ML
Mol Cancer Res; 2008 Mar; 6(3):446-57. PubMed ID: 18337451
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.
Richert MM; Vaidya KS; Mills CN; Wong D; Korz W; Hurst DR; Welch DR
Oncol Rep; 2009 Mar; 21(3):761-7. PubMed ID: 19212637
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
16. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
17. CXCR4-Targeted Necrosis-Inducing Peptidomimetic for Treating Breast Cancer.
Akonnor A; Makise M; Kuniyasu A
ACS Omega; 2023 Jul; 8(27):24467-24476. PubMed ID: 37457445
[TBL] [Abstract][Full Text] [Related]
18. A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells.
Sbrissa D; Semaan L; Govindarajan B; Li Y; Caruthers NJ; Stemmer PM; Cher ML; Sethi S; Vaishampayan U; Shisheva A; Chinni SR
Oncogene; 2019 Jan; 38(3):332-344. PubMed ID: 30111818
[TBL] [Abstract][Full Text] [Related]
19. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor.
Pelus LM; Bian H; Fukuda S; Wong D; Merzouk A; Salari H
Exp Hematol; 2005 Mar; 33(3):295-307. PubMed ID: 15730853
[TBL] [Abstract][Full Text] [Related]
20. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
